Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Putter, H."'
Autor:
Hagenaars, S.C., Groot, S. de, Cohen, D., Dekker, T.J.A., Charehbili, A., Kranenbarg, E.M.K., Carpentier, M.D.D., Pijl, H., Putter, H., Tollenaar, R.A.E.M., Kroep, J.R., Mesker, W.E., Dutch Breast Can
Publikováno v:
International Journal of Cancer, 149(5), 1181-1188. WILEY
International Journal of Cancer
International Journal of Cancer
The tumor‐stroma ratio (TSR) has proven to be a strong prognostic factor in breast cancer, demonstrating better survival for patients with stroma‐low tumors. Since the role of the TSR as a predictive marker for neoadjuvant chemotherapy outcome is
Autor:
Groot, S. de, Lugtenberg, R.T., Cohen, D., Welters, M.J.P., Ehsan, I., Vreeswijk, M.P.G., Smit, V.T.H.B.M., Graaf, H. de, Heijns, J.B., Portielje, J.E.A., Wouw, A.J. van de, Imholz, A.L.T., Kessels, L.W., Vrijaldenhoven, S., Baars, A., Kranenbarg, E.M.K., Duijm-de Carpentier, M., Putter, H., Hoeven, J.J.M. van der, Nortier, J.W.R., Longo, V.D., Pijl, H., Kroep, J.R., Goker, E., Pas, A.J.M., Honkoop, A.H., Dutch Breast Canc Res Grp BOOG
Publikováno v:
Nature Communications, 11
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Nature Communications, 11(1). NATURE PUBLISHING GROUP
Nature Communications, 11, 1
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Nature Communications, 11(1). NATURE PUBLISHING GROUP
Nature Communications, 11, 1
Nature Communications
Short-term fasting protects tumor-bearing mice against the toxic effects of chemotherapy while enhancing therapeutic efficacy. We randomized 131 patients with HER2-negative stage II/III breast cancer, without diabetes and a BMI over 18 kg m−2, to r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::906599da7dc475c6bbe7b08453119143
https://hdl.handle.net/1887/3181368
https://hdl.handle.net/1887/3181368
Autor:
Blok, E.J., Kroep, J.R., Kranenbarg, E.M.K., Duijm-de Carpentier, M., Putter, H., Liefers, G.J., Nortier, J.W.R., Rutgers, E.J.T., Seynaeve, C.M., Velde, C.J.H. van de, IDEAL Study Grp
Publikováno v:
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 168(2), 413-420. Springer New York
Breast Cancer Research and Treatment, 168(2), 413-420
Breast Cancer Research and Treatment, 168(2), 413-420. Springer New York
Breast Cancer Research and Treatment, 168(2), 413-420
Purpose For postmenopausal patients with hormone receptor-positive early breast cancer, the optimal subgroup and duration of extended endocrine therapy is not clear yet. The aim of this study using the IDEAL patient cohort was to identify a subgroup
Autor:
Blok, E.J., Kroep, J.R., Kranenbarg, E.M.K., Duijm-De Carpentier, M., Putter, H., Liefers, G.J., Nortier, J.W.R., Rutgers, E.J.T., Seynaeve, C.M., Velde, C.J.H. van de, IDEAL Study Group, TEAM Study Group
Publikováno v:
European Journal of Cancer, 95, 59-67
European Journal of Cancer, 95, 59-67. Elsevier Ltd.
European Journal of Cancer, 95, 59-67. Elsevier Ltd.
Background Extended endocrine therapy beyond 5 years for postmenopausal breast cancer has been studied within multiple phase III trials. Treatment compliance in these trials is generally poor. In this analysis, we aimed to determine factors that were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d486b65ea2eb3d71c07edc8efa8a0b64
https://hdl.handle.net/1887/95506
https://hdl.handle.net/1887/95506
Autor:
Charehbili, A., Hamdy, N.A.T., Smit, V.T.H.B.M., Kessels, L., Bochove, A. van, Laarhoven, H.W. van, Putter, H., Kranenbarg, E.M.K., Leeuwen-Stok, A.E. van, Hoeven, J.J.M. van der, Velde, C.J.H. van de, Nortier, J.W.R., Kroep, J.R., Dutch Breast Canc Res Grp BOOG
Publikováno v:
Breast, 25, pp. 69-74
The Breast, 25, 69-74
Breast (Edinburgh, Scotland), 25, 69-74. Churchill Livingstone
Breast, 25, 69-74
The Breast, 25, 69-74
Breast (Edinburgh, Scotland), 25, 69-74. Churchill Livingstone
Breast, 25, 69-74
Item does not contain fulltext BACKGROUND: Serum levels of 25-OH vitamin D3 (vitamin D) have been shown to be prognostic for disease-free survival in patients with breast cancer. We investigated the predictive value of these levels for pathological r
Autor:
Charehbili, A., Ven, S. van de, Smit, V.T.H.B.M., Kranenbarg, E.K., Hamdy, N.A.T., Putter, H., Heijns, J.B., Warmerdam, L.J.C. van, Kessels, L., Dercksen, M., Pepels, M.J., Maartense, E., Laarhoven, H.W.M. van, Vriens, B., Wasser, M.N., Leeuwen-Stok, A.E. van, Liefers, G.J., Velde, C.J.H. van de, Nortier, J.W.R., Kroep, J.R., Dutch Breast Canc Res Grp BOOG
Publikováno v:
Annals of Oncology, 25, 5, pp. 998-1004
Annals of Oncology, 25(5), 998-1004. Oxford University Press
Annals of oncology, 25(5), 998-1004. Oxford University Press
Annals of Oncology, 25(5), 998-1004
Annals of Oncology, 25, 998-1004
Annals of Oncology, 25(5), 998-1004. Oxford University Press
Annals of oncology, 25(5), 998-1004. Oxford University Press
Annals of Oncology, 25(5), 998-1004
Annals of Oncology, 25, 998-1004
Item does not contain fulltext BACKGROUND: The role of zoledronic acid (ZA) when added to the neoadjuvant treatment of breast cancer (BC) in enhancing the clinical and pathological response of tumors is unclear. The effect of ZA on the antitumor effe
Autor:
Nes, J.G.H. van, Putter, H., Hezewijk, M. van, Hille, E.T.M., Bartelink, H., Collette, L., Velde, C.J.H. van de, EORTC Breast Canc Grp
Publikováno v:
EJSO-European Journal of Surgical Oncology, 36(7), 617-624
Aims: After treatment, early breast cancer patients undergo follow-up according to standard regimens. After the first year, the main goal is particularly to detect locoregional recurrences (LRR). Our aim was to develop a simple prognostic index to pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21fa6e7496b8d92ea4c3255d3069b16
https://hdl.handle.net/1887/110226
https://hdl.handle.net/1887/110226
Autor:
Nes, J.G.H. van, Seynaeve, C., Maartense, E., Roumen, R.M.H., Jong, R.S. de, Beex, L.V.A.M., Kranenbarg, W.M.M.K., Putter, H., Nortier, J.W.R., Velde, C.J.H. van de, Cooperating Investigators Dutch TE
Publikováno v:
None
Annals of Oncology, 21, 974-82
Annals of Oncology, 21, 5, pp. 974-82
Annals of Oncology, 21(5), 974-982. Elsevier Ltd.
Annals of Oncology, 21(5), 974-982
Annals of Oncology, 974-982
STARTPAGE=974;ENDPAGE=982;TITLE=Annals of Oncology
Annals of Oncology, 21, 974-82
Annals of Oncology, 21, 5, pp. 974-82
Annals of Oncology, 21(5), 974-982. Elsevier Ltd.
Annals of Oncology, 21(5), 974-982
Annals of Oncology, 974-982
STARTPAGE=974;ENDPAGE=982;TITLE=Annals of Oncology
Item does not contain fulltext BACKGROUND: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial investigates the efficacy and safety of adjuvant exemestane alone and in sequence after tamoxifen in postmenopausal women with hormone-sensiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83060b9a7001300842f5c1a466987dbf
https://hdl.handle.net/1887/98888
https://hdl.handle.net/1887/98888